ENB Therapeutics

ENB Therapeutics is a biopharmaceutical company pioneering the development of selective inhibitors of the endothelin B receptor (“ETBR”) to reverse the drug resistance that occurs in over 50% of patients treated with immunotherapy.

The firm's lead product, ENB-003, a first-in-class, selective, small molecule inhibitor of ETBR, has been demonstrated to significantly reduce tumor growth and prolong survival in a variety of immunotherapy-resistant cancers in multiple, preclinical in-vivo studies.

ENB-003 is being developed as a companion agent to unlock the full therapeutic potential of immunotherapy by restoring the ability of T-cells to infiltrate tumors, inhibit metastasis and increase survival.

A proprietary companion diagnostic to detect over-expression of the ETBR provides additional opportunities to identify and expand into multiple indications across the immunotherapy market.